

OM1

Interview Talk

Tim Farrell

Product Manager

Day Zero Diagnostics (DZD)

March 30, 2022

Agenda


1. **DZD**
2. **MicrohmDB**: Data platform for genomics + ML
3. **epiXact**: Outbreak detection for health systems

Day Zero Diagnostics (DZD)

The Future of Microbiology is Digital



Analog, culture-based diagnostics



Slow

Days to weeks to diagnose

Low Resolution

Fails to grow 40% of the time, requires multiple assays for full diagnosis

Limited

Optimized for core diagnostic use-cases



Digital, sequencing-based diagnostics



Fast

Answers within hours

High Resolution

High sensitivity, full genomic interrogation in a single diagnostic


Comprehensive

Capable of comprehensive organisms, HAI & epidemiology, forecasting

Day Zero Diagnostics (DZD)

Advanced ML Algorithms


Complete diagnosis from genomic data



Day Zero Diagnostics (DZD)

Keynome® g-AST

DZD Algorithms Are Trained on MicrohmDB for AST Calls




MicrohmDB: Cloud migration and versioned releases

When I took this over in late 2019, it was poorly designed and technical debt was slowing data integration and sourcing..


Legacy system

- Data not stored in cloud
- Compute not scalable
- Analysis not reproducible
- Data poorly modeled
- Data not versioned



MicrohmDB v1.0


- Data stored in cloud
- Scalable compute
- Analysis reproducible
- Simper, cleaner design
- Data releases quarterly




MicrohmDB: Data integration and QC

.. as we rapidly integrated new data sources, we also wanted to put data quality checks/ verification in place to ensure we were only including high quality data

Legacy system




MicrohmDB v1.0



MicrohmDB: Data platform architecture

Partners and vendors can
transfer sequencing data
directly over FTP


Users can interact with data
through BI dashboards, making
plots and saving common queries



MicrohmDB®

Large Scale Dataset of Pathogen Genomes and AMR Profiles

MicrohmDB: 50,000+ and growing



Customers, Contributors & Collaborators



MASSACHUSETTS
GENERAL HOSPITAL



UCIRVINE



BRIGHAM AND
WOMEN'S HOSPITAL



NEW ENGLAND BAPTIST
HOSPITAL



CANADIAN ANTIMICROBIAL
RESISTANCE ALLIANCE CARA



ARLG
Antibacterial Resistance Leadership Group

blei RESOURCES
SUPPORTING INFECTIOUS DISEASE RESEARCH

New partners since 2019

MicrohmDB: Challenges + future directions


Data versioning is hard

- Use data lakehouse architecture, but data lakes are more conducive to AI R&D workflows and make data versioning easier
- Plan to fully transition to data lake

Data cataloging and provenance is also hard

Plan to transition from ETL → ELT

- Increases development/ data velocity
- Data lake architecture helps this as well



Architecture of modern data platforms [\[Source\]](#)

epiXact: Hospital-acquired infection (HAI) outbreak detection for health systems


- In Fall 2020, became technical and product lead for epiXact*, the company's first commercial offering
- Process:
 - Requested by email or on our website
 - Samples collected from patients suspected of HAI outbreak infection and sent to DZD
 - Sequencing => Analysis => Report



*in addition to
MicrohmDB

epiXact: Key results

- Co-led Clinical Laboratory Improvement Amendments (CLIA) certification with Lab Director, which enabled epiXact to be ordered as a lab test
- Automated analysis and reporting to shorten turnaround time from ~1 week to less than 48 hours, which became an SLA we promised customers
 - Speed was critical for our customers because each day increased likelihood that more patients would be infected by an outbreak
- Updated design of our report for CLIA certification and also to improve CX/ UX
- Projects/ deals grew from ~1 per quarter to ~3-4 per quarter

The image shows two overlapping epiXact reports. The left report is titled 'epiXact Pathogen Identification Report' and includes a table with columns for 'Sample ID', 'Organism', 'MLST', 'SNP', and 'Q-score'. The right report is titled 'eXactPath Report' and includes a table with columns for 'Sample ID', 'Organism', 'MLST', 'SNP', and 'Q-score'. Below the reports is a blue and white seal that reads 'HIPAA SEAL OF CONFIDENCE' and 'HIPAA VERIFIED'.

Report Details

- Determination of outbreak cluster inclusion / exclusion for each sample
- Confirmation of organism ID and Multi-locus Sequence Typing (MLST) typing
- SNP based sequence analysis and distance matrix visualization of relatedness
- Sequencing quality metrics including genome coverage and Q-score

epiXome: New product development


- Worked with our BD team, Marketing and CEO to develop new commercial offerings built on top of epiXact technology
- Part of the business challenge with epiXact is that it was “spiky”, and we often struggled for customers to do regular/ repeat deals with us
- epiXome would be a continuous surveillance service for health systems to proactively detect and control for outbreaks
- I led the new product development process from concept/ design to launch

epiXome®

Unlocking the power of whole-genome sequencing (WGS) for proactive infection monitoring and control

- **Continuous, Scalable Surveillance** – Expansion of epiXact service from episodic investigations to automated, prospective sequencing for real-time monitoring of HAI transmission events.
- **Actionable Genomic Insights** – Leverage the precision of WGS to gain comprehensive, hospital-wide insights into the genomic epidemiology of bacterial infections.
- **Early Detection & Rapid Response** – Enable faster outbreak identification, data-driven infection control strategies, and sequencing-informed feedback to support microbiology lab quality management.
- **Cost-Efficient Infection Control** – Reduce the financial and clinical burden of HAIs through faster response to suspected transmission and prevention of large-scale outbreaks.

[CONTACT US](#)



Thank you!